Quizzes

True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.

True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...

True or false: Targeted therapies—including immune checkpoint inhibitors (ICIs) and mammalian target of rapamycin (mTOR) inhibitors—did not demonstrate improved survival in unselected glioblastoma populations, according to a systematic review...

True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...

True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...

True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...

True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...

Which of the following molecular features were found to be most strongly associated with disease progression in pigmented villonodular synovitis?